FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.22-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

138251000202108: Tralokinumab (substance)


Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 01-Sep 2023. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
5266530014 Tralokinumab (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
5266531013 Tralokinumab en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core


0 descendants.

Expanded Value Set


Outbound Relationships Type Target Active Characteristic Refinability Group Values
Tralokinumab (substance) Is a Monoclonal antibody true Inferred relationship Some
Tralokinumab (substance) Is a Interleukin receptor antagonist false Inferred relationship Some
Tralokinumab (substance) This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. Interleukin receptor antagonist (disposition) false Inferred relationship Some
Tralokinumab (substance) Is a Substance with interleukin-13 receptor antagonist mechanism of action (substance) true Inferred relationship Some
Tralokinumab (substance) This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. Interleukin 13 receptor antagonist (disposition) true Inferred relationship Some

Inbound Relationships Type Active Source Characteristic Refinability Group
Product containing precisely tralokinumab 150 milligram/1 milliliter conventional release solution for injection (clinical drug) The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Tralokinumab (substance) Inferred relationship Some 1
Product containing precisely tralokinumab 150 milligram/1 milliliter conventional release solution for injection (clinical drug) This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. True Tralokinumab (substance) Inferred relationship Some 1
Tralokinumab-containing product in parenteral dose form The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Tralokinumab (substance) Inferred relationship Some 1
Tralokinumab-containing product The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Tralokinumab (substance) Inferred relationship Some 1
Product containing only tralokinumab (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Tralokinumab (substance) Inferred relationship Some 1
Product containing only tralokinumab in parenteral dose form (medicinal product form) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Tralokinumab (substance) Inferred relationship Some 1

This concept is not in any reference sets

Back to Start